10 hours ago
1
Nemes Laszlo/iStock via Getty Images
Eli Lilly (NYSE:LLY) said on Monday that its late-stage trial testing Jaypirca (pirtobrutinib), compared with chemoimmunotherapy, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, met its main goal.
The study showed an improvement in progression-free survival in patients
English (US) ·